In the present study, we hypothesized first that chemerin might be a novel discriminating marker, either alone or on top of the sFlt-1/PlGF ratio, for preeclampsia and its related complications and second that statins might lower placental chemerin synthesis, thereby improving preeclampsia outcome. This evidence concerns the gene RARRES2 and preeclampsia.